GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CKD Bio Corp (XKRX:063160) » Definitions » Cyclically Adjusted PS Ratio

CKD Bio (XKRX:063160) Cyclically Adjusted PS Ratio : 0.83 (As of Jun. 05, 2024)


View and export this data going back to 2001. Start your Free Trial

What is CKD Bio Cyclically Adjusted PS Ratio?

As of today (2024-06-05), CKD Bio's current share price is ₩22350.00. CKD Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₩26,968.60. CKD Bio's Cyclically Adjusted PS Ratio for today is 0.83.

The historical rank and industry rank for CKD Bio's Cyclically Adjusted PS Ratio or its related term are showing as below:

XKRX:063160' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.73   Med: 1.06   Max: 4.45
Current: 0.83

During the past years, CKD Bio's highest Cyclically Adjusted PS Ratio was 4.45. The lowest was 0.73. And the median was 1.06.

XKRX:063160's Cyclically Adjusted PS Ratio is ranked better than
75.54% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs XKRX:063160: 0.83

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CKD Bio's adjusted revenue per share data for the three months ended in Mar. 2024 was ₩8,297.385. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₩26,968.60 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CKD Bio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for CKD Bio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CKD Bio Cyclically Adjusted PS Ratio Chart

CKD Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.30 3.53 1.76 0.94 0.89

CKD Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.94 0.86 0.89 0.89

Competitive Comparison of CKD Bio's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, CKD Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CKD Bio's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CKD Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CKD Bio's Cyclically Adjusted PS Ratio falls into.



CKD Bio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CKD Bio's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22350.00/26968.6
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CKD Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CKD Bio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8297.385/118.8477*118.8477
=8,297.385

Current CPI (Mar. 2024) = 118.8477.

CKD Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4,982.923 99.353 5,960.655
201409 4,867.763 99.608 5,807.992
201412 4,616.373 99.098 5,536.391
201503 4,496.264 99.720 5,358.711
201506 5,267.087 100.050 6,256.683
201509 5,008.683 100.110 5,946.164
201512 5,031.871 100.220 5,967.135
201603 5,347.604 100.560 6,320.112
201606 5,141.168 100.790 6,062.268
201609 5,462.436 101.460 6,398.561
201612 5,040.432 101.560 5,898.422
201703 5,575.026 102.850 6,442.188
201706 5,686.168 102.610 6,585.986
201709 5,350.724 103.490 6,144.760
201712 5,334.618 102.990 6,156.006
201803 5,710.169 104.100 6,519.121
201806 5,730.940 104.130 6,540.949
201809 6,044.085 105.650 6,799.106
201812 5,632.074 104.350 6,414.557
201903 5,807.997 104.490 6,606.059
201906 6,115.631 104.880 6,930.098
201909 6,491.194 105.200 7,333.303
201912 8,698.772 105.120 9,834.751
202003 5,645.820 105.540 6,357.710
202006 6,452.611 104.870 7,312.654
202009 6,062.930 106.200 6,784.984
202012 4,876.836 105.765 5,480.060
202103 6,106.833 107.357 6,760.451
202106 6,829.980 107.579 7,545.436
202109 6,922.450 108.759 7,564.576
202112 6,065.101 109.676 6,572.274
202203 8,559.523 111.806 9,098.630
202206 6,681.212 114.083 6,960.266
202209 6,852.166 114.831 7,091.831
202212 6,365.503 115.200 6,567.049
202303 7,965.119 116.550 8,122.174
202306 7,105.409 117.140 7,209.000
202309 7,718.351 119.111 7,701.276
202312 6,440.574 118.848 6,440.574
202403 8,297.385 118.848 8,297.385

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CKD Bio  (XKRX:063160) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CKD Bio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of CKD Bio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CKD Bio (XKRX:063160) Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjeongno 3-ga, Seodaemun-gu, Seoul, KOR, 120-756
CKD Bio Corp is engaged in manufacturing and distribution of pharmaceutical materials and medicines. Its products portfolio include antibiotic, lactamase inhibitors, antituberculosis, antidiabetics, immunosuppressants, antihyperlipidemics, intermediates, and probiotics.

CKD Bio (XKRX:063160) Headlines

No Headlines